PURPOSE: There has been no risk assessment model for bladder cancer (BC). We developed the first model incorporating mutagen sensitivity and epidemiologic factors to predict BC risk. PATIENTS AND METHODS: We used epidemiologic and genetic data from a large case-control study to build the models and constructed receiver operating characteristic curves. The area under the curve (AUC) was used to evaluate model discriminatory ability. We also projected absolute risk of developing BC by taking into account competing causes of death. RESULTS: The study included 678 white BC patients and 678 controls. Significant risk factors in the epidemiologic model included pack-years smoked and exposures to diesel, aromatic amines, dry cleaning fluids, radioactive materials, and arsenic. This model yielded good discriminatory ability (AUC = 0.70; 95% CI, 0.67 to 0.73). When mutagen sensitivity data were incorporated, the AUC increased to 0.80 (95% CI, 0.72 to 0.82). The models showed excellent concordance in the internal validation. We also computed an easy to use ordinal risk score and provided examples for projecting absolute risk. CONCLUSION: We have developed the first risk prediction model for BC. The enhanced model integrating the genetic factor exhibited excellent discriminatory ability. Our model only requires an individual to answer a few simple questions during a clinic visit to project individualized probability. This model may be used as a basis for developing a Web-based tool for BC risk assessment. Validation of our model in an external population is an essential next step towards practical use in the clinical setting.
PURPOSE: There has been no risk assessment model for bladder cancer (BC). We developed the first model incorporating mutagen sensitivity and epidemiologic factors to predict BC risk. PATIENTS AND METHODS: We used epidemiologic and genetic data from a large case-control study to build the models and constructed receiver operating characteristic curves. The area under the curve (AUC) was used to evaluate model discriminatory ability. We also projected absolute risk of developing BC by taking into account competing causes of death. RESULTS: The study included 678 white BC patients and 678 controls. Significant risk factors in the epidemiologic model included pack-years smoked and exposures to diesel, aromatic amines, dry cleaning fluids, radioactive materials, and arsenic. This model yielded good discriminatory ability (AUC = 0.70; 95% CI, 0.67 to 0.73). When mutagen sensitivity data were incorporated, the AUC increased to 0.80 (95% CI, 0.72 to 0.82). The models showed excellent concordance in the internal validation. We also computed an easy to use ordinal risk score and provided examples for projecting absolute risk. CONCLUSION: We have developed the first risk prediction model for BC. The enhanced model integrating the genetic factor exhibited excellent discriminatory ability. Our model only requires an individual to answer a few simple questions during a clinic visit to project individualized probability. This model may be used as a basis for developing a Web-based tool for BC risk assessment. Validation of our model in an external population is an essential next step towards practical use in the clinical setting.
Authors: Jie Lin; Michele R Forman; Jianming Wang; H Barton Grossman; Meng Chen; Colin P Dinney; Ernest T Hawk; Xifeng Wu Journal: Int J Cancer Date: 2012-03-06 Impact factor: 7.396
Authors: Carmen J Marsit; Devin C Koestler; Brock C Christensen; Margaret R Karagas; E Andres Houseman; Karl T Kelsey Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 44.544
Authors: Montserrat Garcia-Closas; Nathaniel Rothman; Jonine D Figueroa; Ludmila Prokunina-Olsson; Summer S Han; Dalsu Baris; Eric J Jacobs; Nuria Malats; Immaculata De Vivo; Demetrius Albanes; Mark P Purdue; Sapna Sharma; Yi-Ping Fu; Manolis Kogevinas; Zhaoming Wang; Wei Tang; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Margaret R Karagas; Alan Schned; Gerald Andriole; Robert Grubb; Amanda Black; Susan M Gapstur; Michael Thun; William Ryan Diver; Stephanie J Weinstein; Jarmo Virtamo; David J Hunter; Neil Caporaso; Maria Teresa Landi; Amy Hutchinson; Laurie Burdett; Kevin B Jacobs; Meredith Yeager; Joseph F Fraumeni; Stephen J Chanock; Debra T Silverman; Nilanjan Chatterjee Journal: Cancer Res Date: 2013-03-27 Impact factor: 12.701
Authors: A M D'Amelio; A Cassidy; K Asomaning; O Y Raji; S W Duffy; J K Field; M R Spitz; D Christiani; C J Etzel Journal: Br J Cancer Date: 2010-06-29 Impact factor: 7.640
Authors: Mariana C Stern; Jie Lin; Jonine D Figueroa; Karl T Kelsey; Anne E Kiltie; Jian-Min Yuan; Giuseppe Matullo; Tony Fletcher; Simone Benhamou; Jack A Taylor; Donatella Placidi; Zuo-Feng Zhang; Gunnar Steineck; Nathaniel Rothman; Manolis Kogevinas; Debra Silverman; Nuria Malats; Stephen Chanock; Xifeng Wu; Margaret R Karagas; Angeline S Andrew; Heather H Nelson; D Timothy Bishop; Sei Chung Sak; Ananya Choudhury; Jennifer H Barrett; Faye Elliot; Román Corral; Amit D Joshi; Manuela Gago-Dominguez; Victoria K Cortessis; Yong-Bing Xiang; Yu-Tang Gao; Paolo Vineis; Carlotta Sacerdote; Simonetta Guarrera; Silvia Polidoro; Alessandra Allione; Eugen Gurzau; Kvetoslava Koppova; Rajiv Kumar; Peter Rudnai; Stefano Porru; Angela Carta; Marcello Campagna; Cecilia Arici; Sung Shim Lani Park; Montserrat Garcia-Closas Journal: Cancer Res Date: 2009-08-25 Impact factor: 12.701